![]() The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey. The company was formerly known as Global Group Enterprises Corp. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. 3 Reasons Why Apple’s 30% Rally Has Legs. ![]() Hypercharge Networks: Up Triple Digits, But What’s The Big Deal?.2 Beautiful Investments In A Growing Industry.What Factors Will Drive S&P 500 Performance This Year?.For Tyme Technologies stock forecast for 2024, 12. Walmart Makes Moves for Efficiency with Robots to Spur Sales The average Tyme Technologies stock forecast 2023 represents a -1.32 decrease from the last price of 1.23.FedEx Takes Flight Analysts See More Gains Ahead.3 Low-Cost Stock ETFs That Are Crushing It This Year.The WD-40 Company Bottoms With Reversal In Sight.First Republic Bank Is A Speculative Play, Here’s Why.Costco Sales Disappoint, Markets Are Missing This Upside Driver. ![]() After all, the newsletter they have run for over a decade, Motley.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |